Phathom Pharmaceuticals told investors on April 30, 2026 that it was "maintaining" its FY 2026 revenue guidance of $320 million to $345 million. Weeks later, the Company cut that outlook to $310 million...
Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT shareholders...
~1.7 million total VOQUEZNA ® prescriptions filled to date Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 Q2 operating expenses of $63.1 million,...
Barchart Research What to Expect from PHAT Earnings PHAT Generated July 29, 2026 Current Price $11.64 EPS Estimate $$-0.15 Consensus Rating Strong Buy Average Move 7.63% Phathom Pharmaceuticals Reports...
FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in...
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts ...
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...
~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses...